Henrik Ljung will take the role of Chief Financial Officer, CFO, in Qlife Holding AB.

Henrik Ljung holds an MBA from Lund’s university and has extensive experience as CFO in listed companies such as Spectracure AB, Acconeer AB and AB Sardus. He will be part of Qlife Holdings' management and report directly to CEO Thomas Warthoe.

"Henrik Ljung brings broad experience to Qlife from financial reporting, IR, business control, finance management and corporate governance, all with a focus on fast-growing companies in the early stages. It is with great pleasure that I welcome Henrik to our company," says Thomas Warthoe, CEO of Qlife Holding.

"I look forward to joining Qlife and taking on the role of CFO. Qlife is on an exciting growth journey that is just beginning, and I am personally attracted to companies with a business that contributes to society, which Qlife clearly does through its product range," says Henrik Ljung.

Lars Bangsgaard, who has assumed the role of CFO both in the operating company Qlife ApS in Denmark and in the parent company Qlife Holding AB, will continue in his role as CFO in Qlife ApS.

Henrik Ljung will begin his work with Qlife on July 1, 2020.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

About Qlife

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.